Cart
sales@molnova.com
Ac-IEPD-AFC
CAS No. 1135417-31-0
Ac-IEPD-AFC( IEPD )
Catalog No. M29827 CAS No. 1135417-31-0
Ac-IEPD-AFC (IEPD) is a substrate of Granzyme B.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
Biological Information
-
Product NameAc-IEPD-AFC
-
NoteResearch use only, not for human use.
-
Brief DescriptionAc-IEPD-AFC (IEPD) is a substrate of Granzyme B.
-
DescriptionAc-IEPD-AFC (IEPD) is a substrate of Granzyme B.(In Vitro):The Km of human granzyme B for Ac-IEPD-AFC in granzyme B assay buffer is 585 μM.
-
In VitroThe Km of human granzyme B for Ac-IEPD-AFC in granzyme B assay buffer is 585 μM.
-
In Vivo——
-
SynonymsIEPD
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1135417-31-0
-
Formula Weight725.67
-
Molecular FormulaC32H38F3N5O11
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (137.80 mM)
-
SMILES——
-
Chemical NameSequence:N-acetyl-Ile-Glu-Pro-Asp
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
Pak SC, et al. SRP-2 is a cross-class inhibitor that participates in postembryonic development of the nematode Caenorhabditis elegans: initial characterization of the clade L serpins. J Biol Chem. 2004 Apr 9;279(15):15448-59.
molnova catalog
related products
-
PI-55
PI-55 (6-(2-hydroxy-3-methylbenzylamino)purine) is a cytokinin receptor inhibitor that exhibits structural similarity to 6-benzylaminopurine (BAP).
-
MSNBA
MSNBA is a selective and potent inhibitor of fructose transport through GLUT5 and also acts as a probe of the GLUT5 transporter. MSNBA inhibited GLUT5 fructose uptake in MCF7 cells with KI of 3.2±0.4 μM.
-
Atracurium besylate
Atracurium besylate is a non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.
